Please assess the completion status of the following clinical trial:

Trial Title: Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Age ≥1 year~* Weight \>10 Kg~* P. falciparum mono-infection, density of at least 20 parasites/μL~* Axillary temperature \< 37.5ºC~* Resident in the study area and willingness to reside for the duration of the study~* Written informed consent (plus an assent in children \>12years of age)~Exclusion Criteria:~* G6PD Deficiency Haemoglobin \<8g/dl~  * Known allergy to any of the study medications~ * Known Pregnancy or breastfeeding~ * Clear/documented history of anti-malarial treatment 2 weeks before contact with study team~ * History of blood transfusion in the previous 3 months~ * Any chronic or acute conditions that might interfere with the study as judged by the research clinician~ * History of sickle cell anaemia

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Eurartesim (control) (Type: OTHER): All participants will receive a complete course of DHA-PPQ (Eurartesim)
- Primaquine 0.75mg base/kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.75mg/kg body weight
- Primaquine 0.4mg base /kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.4mg base/kg Body weight
- Primaquine 0.2mg base/kg (Type: EXPERIMENTAL): Participants will be randomized to receive a complete course of DHA-PPQ plus a single dose of PQ at 0.2mg base/kg body weight

Based on this trial design, predict the completion outcome and termination type (if applicable).